Daptomycin-nonsusceptible Staphylococcus aureus: The role of combination therapy with daptomycin and gentamicin

Genes

Volumn 6, Issue 4, 2015, Pages 1256-1267

  Jiang, Jhih Hang ^a   Peleg, Anton Y ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Combination therapy; MRSA; S. aureus; Synergy; Time kill studies; VISA

Indexed keywords

DAPTOMYCIN; GENTAMICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; MUTATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

EID: 84949546164     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes6041256     Document Type: Article

References (44)

1. Fowler, V. G., Jr.; Boucher, H. W.; Corey, G. R.; Abrutyn, E.; Karchmer, A. W.; Rupp, M. E.; Levine, D. P.; Chambers, H. F.; Tally, F. P.; Vigliani, G. A.; et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by staphylococcus aureus. N. Engl. J. Med. 2006, 355, 653-665.
2. Marty, F. M.; Yeh, W. W.; Wennersten, C. B.; Venkataraman, L.; Albano, E.; Alyea, E. P.; Gold, H. S.; Baden, L. R.; Pillai, S. K. Emergence of a clinical daptomycin-resistant staphylococcus aureus isolate during treatment of methicillin-resistant staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 2006, 44, 595-597.
3. Friedman, L.; Alder, J. D.; Silverman, J. A. Genetic changes that correlate with reduced susceptibility to daptomycin in staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50, 2137-2145.
4. Ernst, C. M.; Staubitz, P.; Mishra, N. N.; Yang, S. J.; Hornig, G.; Kalbacher, H.; Bayer, A. S.; Kraus, D.; Peschel, A. The bacterial defensin resistance protein mprf consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathogens 2009, 5, e1000660.
5. Mishra, N. N.; Yang, S. J.; Sawa, A.; Rubio, A.; Nast, C. C.; Yeaman, M. R.; Bayer, A. S. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53, 2312-2318.
6. Rubio, A.; Moore, J.; Varoglu, M.; Conrad, M.; Chu, M.; Shaw, W.; Silverman, J. A. LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and-resistant isolates of staphylococcus aureus with mutations in Mprf. Mol. Membr. Biol. 2012, 29, 1-8.
7. Peleg, A. Y.; Miyakis, S.; Ward, D. V.; Earl, A. M.; Rubio, A.; Cameron, D. R.; Pillai, S.; Moellering, R. C., Jr.; Eliopoulos, G. M. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of staphylococcus aureus. PloS ONE 2012, 7, e28316.
8. Dubrac, S.; Boneca, I. G.; Poupel, O.; Msadek, T. New insights into the walk/walr (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm formation in staphylococcus aureus. J. Bacteriol. 2007, 189, 8257-8269.
9. Cui, L.; Tominaga, E.; Neoh, H. M.; Hiramatsu, K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50, 1079-1082.
10. Cameron, D. R.; Ward, D. V.; Kostoulias, X.; Howden, B. P.; Moellering, R. C., Jr.; Eliopoulos, G. M.; Peleg, A. Y. Serine/threonine phosphatase stp1 contributes to reduced susceptibility to vancomycin and virulence in staphylococcus aureus. J. Infectious Dis. 2012, 205, 1677-1687.
11. Howden, B. P.; McEvoy, C. R.; Allen, D. L.; Chua, K.; Gao, W.; Harrison, P. F.; Bell, J.; Coombs, G.; Bennett-Wood, V.; Porter, J. L.; et al. Evolution of multidrug resistance during staphylococcus aureus infection involves mutation of the essential two component regulator walkr. PLoS Pathogens 2011, 7, e1002359.
12. Debbia, E.; Pesce, A.; Schito, G. C. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob. Agents Chemother. 1988, 32, 279-281.
13. Agence francaise de securite sanitaire des produits de, s. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med. Mal. Infectieuses 2012, 42, 301-308.
14. Snydman, D. R.; McDermott, L. A.; Jacobus, N. V. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against staphylococcus aureus and enterococci by FIC index and timed-kill curves. J. Chemother. 2005, 17, 614-621.
15. Tsuji, B. T.; Rybak, M. J. Etest synergy testing of clinical isolates of staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn. Microbiol. Infectious Dis. 2006, 54, 73-77.
16. Tsuji, B. T.; Rybak, M. J. Short-course gentamicin in combination with daptomycin or vancomycin against staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 2005, 49, 2735-2745.
17. Credito, K.; Lin, G.; Appelbaum, P. C. Activity of daptomycin alone and in combination with rifampin and gentamicin against staphylococcus aureus assessed by time-kill methodology. Antimicrob. Agents Chemother. 2007, 51, 1504-1507.
18. Baltch, A. L.; Ritz, W. J.; Bopp, L. H.; Michelsen, P. B.; Smith, R. P. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against staphylococcus aureus. Antimicrob. Agents Chemother. 2007, 51, 1559-1562.
19. Baltch, A. L.; Ritz, W. J.; Bopp, L. H.; Michelsen, P.; Smith, R. P. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth. Antimicrob. Agents Chemother. 2008, 52, 1829-1833.
20. Miro, J. M.; Garcia-de-la-Maria, C.; Armero, Y.; Soy, D.; Moreno, A.; del Rio, A.; Almela, M.; Sarasa, M.; Mestres, C. A.; Gatell, J. M.; et al. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53, 4172-4177.
21. Entenza, J. M.; Giddey, M.; Vouillamoz, J.; Moreillon, P. In vitro prevention of the emergence of daptomycin resistance in staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int. J. Antimicrob. Agents 2010, 35, 451-456.
22. LaPlante, K. L.; Woodmansee, S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob. Agents Chemother. 2009, 53, 3880-3886.
23. LaPlante, K. L.; Rybak, M. J. Impact of high-inoculum staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 2004, 48, 4665-4672.
24. DeRyke, C. A.; Sutherland, C.; Zhang, B.; Nicolau, D. P.; Kuti, J. L. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of staphylococcus aureus and enterococcus species. Antimicrob. Agents chemother. 2006, 50, 3529-3534.
25. Rose, W. E.; Leonard, S. N.; Rybak, M. J. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 2008, 52, 3061-3067.
26. Steenbergen, J. N.; Mohr, J. F.; Thorne, G. M. Effects of daptomycin in combination with other antimicrobial agents: A review of in vitro and animal model studies. J. Antimicrob. Chemother. 2009, 64, 1130-1138.
27. Dvorchik, B. H.; Brazier, D.; DeBruin, M. F.; Arbeit, R. D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 2003, 47, 1318-1323.
28. Montange, D.; Berthier, F.; Leclerc, G.; Serre, A.; Jeunet, L.; Berard, M.; Muret, P.; Vettoretti, L.; Leroy, J.; Hoen, B.; et al. Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob. Agents Chemother. 2014, 58, 3991-3996.
29. Traunmuller, F.; Schintler, M. V.; Metzler, J.; Spendel, S.; Mauric, O.; Popovic, M.; Konz, K. H.; Scharnagl, E.; Joukhadar, C. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J. Antimicrob. Chemother. 2010, 65, 1252-1257.
30. Peleg, A. Y.; Monga, D.; Pillai, S.; Mylonakis, E.; Moellering, R. C., Jr.; Eliopoulos, G. M. Reduced susceptibility to vancomycin influences pathogenicity in staphylococcus aureus infection. J. Infectious Dis. 2009, 199, 532-536.
31. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria that Grow Aerobically. In Approved Standard M7-A5, 5th ed.; Committee for Clinical Laboratory Standards: Wayne, PA, USA, 2000.
32. Pillai, S. K.; Moellering, R. C., Jr.; Eliopoulos, G. M. Antimicrobial Combinations. In Antibiotics in Laboratory Medicine, 5th ed.; Lorian, V., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005; pp. 365-440.
33. Zammit, M. C.; Fiorentino, L.; Cassar, K.; Azzopardi, L. M.; LaFerla, G. Factors affecting gentamicin penetration in lower extremity ischemic tissues with ulcers. Int. J. Lower Extremity Wounds 2011, 10, 130-137.
34. Lorentzen, H.; Kallehave, F.; Kolmos, H. J.; Knigge, U.; Bulow, J.; Gottrup, F. Gentamicin concentrations in human subcutaneous tissue. Antimicrob. Agents Chemother. 1996, 40, 1785-1789.
35. Gill, M. A.; Cohen, J. L.; Chenella, F. C.; Hisayasu, G. H.; Chandrasoma, P.; Warnecke, G. M.; Chung, H.; Heseltine, P. N.; Yellin, A. E.; Berne, T. V. Gentamicin penetration into diseased appendix tissue. Ther. Drug Monit. 1984, 6, 298-301.
36. Beraud, G.; le Moal, G.; Elsendoorn, A.; Tattevin, P.; Godet, C.; Alfandari, S.; Couet, W.; Roblot, P.; Roblot, F. A Survey on the use of gentamicin in infective endocarditis. Eur. J. Clin. Microbiol. Infectious Dis. 2012, 31, 1413-1418.
37. Kim, A.; Suecof, L. A.; Sutherland, C. A.; Gao, L.; Kuti, J. L.; Nicolau, D. P. In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob. Agents Chemother. 2008, 52, 3941-3946.
38. Gika, H. G.; Michopoulos, F.; Divanis, D.; Metalidis, S.; Nikolaidis, P.; Theodoridis, G. A. Daptomycin determination by liquid chromatography-mass spectrometry in peritoneal fluid, blood plasma, and urine of clinical patients receiving peritoneal dialysis treatment. Anal. Bioanal. Chem. 2010, 397, 2191-2197.
39. Jiang, J.-H.; Peleg, A. Y. Monash University, Clayton, Australia. Unpublished results, 2015.
40. Yang, S. J.; Kreiswirth, B. N.; Sakoulas, G.; Yeaman, M. R.; Xiong, Y. Q.; Sawa, A.; Bayer, A. S. Enhanced expression of dltabcd is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of staphylococcus aureus. J. Infectious Dis. 2009, 200, 1916-1920.
41. Yang, S. J.; Bayer, A. S.; Mishra, N. N.; Meehl, M.; Ledala, N.; Yeaman, M. R.; Xiong, Y. Q.; Cheung, A. L. The staphylococcus aureus two-component regulatory system, grars, senses and confers resistance to selected cationic antimicrobial peptides. Infection Immunity 2012, 80, 74-81.
42. Camargo, I. L.; Neoh, H. M.; Cui, L.; Hiramatsu, K. Serial daptomycin selection generates daptomycin-nonsusceptible staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 2008, 52, 4289-4299.
43. Blake, K. L.; O'Neill, A. J. Transposon library screening for identification of genetic loci participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents. J. Antimicrob. Chemother. 2013, 68, 12-16.
44. Akins, R. L.; Rybak, M. J. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. 2000, 44, 1925-1929.